Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
Status
Public
HQ
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
Founded
2016
Employees
9
Programs
99
Drugs
26
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Lakefront Biotherapeutics NV projects

29 ClinicalTrials.gov programs sponsored by Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

29 programs

Clinical programs

  1. Filgotinib

    Lakefront Biotherapeutics NV

    Fistulizing Crohn's Disease

    phase 2 small molecule completed

    1 trial

  2. Filgotinib

    Lakefront Biotherapeutics NV

    Inflammatory Bowel Disease

    phase 2 small molecule terminated

    1 trial

  3. Filgotinib

    Lakefront Biotherapeutics NV

    Noninfectious Uveitis

    phase 2 small molecule terminated

    1 trial

  4. Filgotinib

    Lakefront Biotherapeutics NV

    Small Bowel Crohn's Disease

    phase 2 small molecule completed

    1 trial

  5. GLPG0259 oral capsule

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  6. GLPG0634

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  7. GLPG0634

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    4 trials

  8. GLPG0974

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  9. GLPG1205

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  10. GLPG1205

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  11. GLPG1690

    Lakefront Biotherapeutics NV

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  12. GLPG1690 600 mg QD

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  13. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  14. GLPG1972

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  15. GLPG2222 150 mg q.d.

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  16. GLPG2222 50 mg

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  17. GLPG2737

    Lakefront Biotherapeutics NV

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  18. GLPG2737

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  19. GLPG3667

    Lakefront Biotherapeutics NV

    Dermatomyositis

    phase 2 small molecule completed

    1 trial

  20. GLPG3667

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  21. GLPG3970

    Lakefront Biotherapeutics NV

    Primary Sjögren Syndrome

    phase 2 small molecule terminated

    1 trial

  22. GLPG3970

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  23. GLPG3970

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  24. GLPG5101

    Lakefront Biotherapeutics NV

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 gene therapy active

    1 trial

  25. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  26. Lanraplenib

    Lakefront Biotherapeutics NV

    Sjogren's Syndrome

    phase 2 small molecule completed

    1 trial

  27. MOR 106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  28. MOR106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  29. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Lakefront Biotherapeutics NV have?

29 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.